These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 12483127

  • 21. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [Abstract] [Full Text] [Related]

  • 22. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 23. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 24. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

  • 25. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep 06; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 26. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.
    Can J Clin Pharmacol; 2001 Sep 06; 8(4):188-98. PubMed ID: 11743591
    [Abstract] [Full Text] [Related]

  • 27. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.
    Am J Gastroenterol; 2003 Apr 06; 98(4):833-8. PubMed ID: 12738464
    [Abstract] [Full Text] [Related]

  • 28. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 29. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 30. Infliximab in Crohn's disease: first anniversary clinical experience.
    Cohen RD, Tsang JF, Hanauer SB.
    Am J Gastroenterol; 2000 Dec 13; 95(12):3469-77. PubMed ID: 11151879
    [Abstract] [Full Text] [Related]

  • 31. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.
    Colorectal Dis; 2005 Mar 13; 7(2):164-8. PubMed ID: 15720356
    [Abstract] [Full Text] [Related]

  • 32. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I, Yeshurun D, Hallak A, Horowitz N, Tiomny E, Reif S, Halpern Z, Rachmilewitz D.
    Harefuah; 2001 Apr 13; 140(4):289-93, 368. PubMed ID: 11303390
    [Abstract] [Full Text] [Related]

  • 33. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS, Markowitz J, Wyllie R.
    J Pediatr; 2000 Aug 13; 137(2):192-6. PubMed ID: 10931411
    [Abstract] [Full Text] [Related]

  • 34. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ.
    Am J Gastroenterol; 2004 May 13; 99(5):878-83. PubMed ID: 15128354
    [Abstract] [Full Text] [Related]

  • 35. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 13; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 36. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR.
    Ital J Gastroenterol Hepatol; 1999 Oct 13; 31(6):519-20. PubMed ID: 10575573
    [Abstract] [Full Text] [Related]

  • 37. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.
    Hepatogastroenterology; 2003 Oct 13; 50(52):952-6. PubMed ID: 12845957
    [Abstract] [Full Text] [Related]

  • 38. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN.
    Am J Gastroenterol; 2003 Jan 13; 98(1):104-11. PubMed ID: 12526944
    [Abstract] [Full Text] [Related]

  • 39. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

  • 40. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 01; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.